Northwestern Mutual Wealth Management Co. Has $96,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Northwestern Mutual Wealth Management Co. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 468.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 802 shares of the medical device company’s stock after purchasing an additional 661 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in DexCom were worth $96,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Great West Life Assurance Co. Can boosted its stake in DexCom by 141.1% in the fourth quarter. Great West Life Assurance Co. Can now owns 24,305 shares of the medical device company’s stock valued at $2,780,000 after acquiring an additional 14,225 shares in the last quarter. Virginia Retirement Systems ET AL boosted its stake in DexCom by 230.6% in the first quarter. Virginia Retirement Systems ET AL now owns 16,200 shares of the medical device company’s stock valued at $1,929,000 after acquiring an additional 11,300 shares in the last quarter. Two Sigma Advisers LP boosted its stake in DexCom by 1,493.1% in the fourth quarter. Two Sigma Advisers LP now owns 694,814 shares of the medical device company’s stock valued at $83,239,000 after acquiring an additional 651,200 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its stake in DexCom by 33.2% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 181,252 shares of the medical device company’s stock valued at $21,714,000 after acquiring an additional 45,149 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its stake in DexCom by 32.0% in the first quarter. Robeco Institutional Asset Management B.V. now owns 162,127 shares of the medical device company’s stock valued at $19,307,000 after acquiring an additional 39,300 shares in the last quarter. Hedge funds and other institutional investors own 96.50% of the company’s stock.

NASDAQ DXCM opened at $146.32 on Friday. The company has a debt-to-equity ratio of 1.57, a quick ratio of 6.75 and a current ratio of 7.18. DexCom, Inc. has a 52-week low of $90.61 and a 52-week high of $156.16. The stock has a market cap of $13.23 billion, a P/E ratio of 487.73 and a beta of 0.70.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.12. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. The firm had revenue of $280.50 million for the quarter, compared to analyst estimates of $246.10 million. During the same quarter last year, the company posted ($0.30) earnings per share. The business’s revenue was up 52.1% on a year-over-year basis. Analysts predict that DexCom, Inc. will post 0.81 earnings per share for the current fiscal year.

In related news, EVP Steven Robert Pacelli sold 3,596 shares of the firm’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $140.04, for a total transaction of $503,583.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $127.03, for a total value of $50,812.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,234 shares of company stock worth $7,614,307. Corporate insiders own 1.80% of the company’s stock.

Several research firms have issued reports on DXCM. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Friday, June 7th. Northland Securities restated a “hold” rating and issued a $125.00 price objective on shares of DexCom in a research note on Thursday, June 6th. Zacks Investment Research upgraded shares of DexCom from a “hold” rating to a “buy” rating and set a $138.00 price objective for the company in a research note on Monday, May 6th. BMO Capital Markets upped their price objective on shares of DexCom from $167.00 to $172.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, Raymond James decreased their price objective on shares of DexCom from $160.00 to $150.00 and set an “outperform” rating for the company in a research note on Thursday, May 2nd. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $150.65.

TRADEMARK VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2019/06/14/northwestern-mutual-wealth-management-co-has-96000-position-in-dexcom-inc-nasdaqdxcm.html.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: The basics of gap trading strategies

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.